Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma
Status:
Completed
Trial end date:
2020-06-09
Target enrollment:
Participant gender:
Summary
This study will evaluate the use of nivolumab before surgery in patients with high-risk clear
cell renal cell carcinoma who are eligible for nephrectomy. Nivolumab is an antibody that may
help activate the immune system by blocking the function of an inhibitory molecule,
Programmed cell death-1 (PD-1).
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins